May 1, 1981BloodOpen Access

Inhibition of von Willebrand factor-dependent platelet function by increased platelet cyclic AMP and its prevention by cytoskeleton- disrupting agents

View Full Paper

Ask AI

Bookmark

Structured PICO

Population

Platelet-rich plasma and formaldehyde-fixed platelets (in vitro model)

Intervention

Agents that raise platelet cyclic AMP (PGI2, PGE1, dibutyryl cyclic AMP)

Comparator

Untreated platelets or platelets preincubated with cytoskeleton-disrupting agents (colchicine, vinblastine, cytochalasin-D, cytochalasin-B)

Outcome

Initial slope of platelet aggregation induced by ristocetin and bovine von Willebrand factorsurrogate

Agents that increase platelet cAMP inhibit platelet adhesion via a mechanism dependent on the platelet cytoskeleton.

No takes yet. Share an insight, caveat, or question.

Animal data link cAMP to cytoskeleton-dependent platelet inhibition; leaves open human antithrombotic translation.

BS Coller (1981) studied this question.

View Full Paper

Ask AI

Bookmark